Clear, independent answers on research peptides — written for the UK.
Evidence-graded compound profiles, vetted vendor reviews, and UK regulatory clarity. No vendor advertising. No hype. Free to read.
Content Pillars
Five places to start.
Whether you're reading your first compound profile or designing your fifth protocol stack — the depth is here.
Compound Education
Evidence-graded profiles for every peptide that matters.
Browse compounds02UK Regulatory Clarity
What's legal, what's grey, and what's changed in 2026.
Read the legal guide03Vendor Reviews
Independent assessments with third-party purity testing.
Compare vendors04Protocol Guidance
Reconstitution, storage, and research protocols — grounded in the published literature.
View protocol library05Blood Work & Monitoring
What to test, when to test, what the numbers mean.
Open the panel guideFeatured Profiles
The most-read compound profiles this month.
Every profile grades its evidence base explicitly — so you always know where you stand.
5-Amino-1MQ
An NNMT inhibitor peptide researched for fat loss and metabolic function
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule peptide derivative that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme implicated in fat cell metabolism and energy regulation. Research is primarily preclinical — cell and animal models show promising effects on fat loss and metabolic markers, but no human clinical trials have been published as of 2025. Researchers discuss it in the context of obesity, metabolic syndrome, and body composition, though the evidence base remains early-stage.
Amycretin
Dual amylin/calcitonin receptor agonist for obesity — early-phase investigational peptide
Amycretin is an investigational dual amylin and calcitonin receptor agonist developed by Novo Nordisk for the treatment of obesity. It is currently in Phase 2 clinical trials. Early-phase data presented in 2024 suggested substantial weight loss over a short treatment period, drawing significant attention as a potential next-generation obesity therapy. All content here is for research and educational purposes only.
AOD-9604
Modified hGH fragment peptide researched for targeted fat metabolism
AOD-9604 is a synthetic 15-amino-acid peptide based on the C-terminal fragment (residues 177–191) of human growth hormone. Developed in the late 1990s by Metabolic Pharmaceuticals, it was designed to replicate the fat-burning (lipolytic) effects of hGH without its effects on blood glucose, tissue growth, or IGF-1. It reached Phase II human clinical trials, making it one of the more clinically researched peptides in the fat-loss category.
BPC-157
A synthetic gastric peptide studied for tissue repair in animal models — research use only.
BPC-157 is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. It is widely studied in animal models for its apparent effects on tendon, ligament, muscle and gut healing, and on blood-vessel formation (angiogenesis). The research base is almost entirely preclinical (rodent) — there are no published human clinical trials establishing efficacy or safety. This profile is for research and educational purposes only.
Cagrilintide
Long-acting amylin analogue in development as CagriSema (with semaglutide) for obesity and type 2 diabetes
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, designed to mimic the satiety hormone amylin. It is primarily being developed in combination with semaglutide as 'CagriSema' — a once-weekly co-formulation targeting both amylin and GLP-1 pathways. Phase 3 topline results (REDEFINE-2) reported in early 2025 showed CagriSema achieved superior HbA1c reduction and weight loss compared to semaglutide alone in type 2 diabetes. Cagrilintide is not a licensed medicine in the UK.
Cagrisema
Cagrilintide + semaglutide dual amylin and GLP-1 receptor agonist combination under development by Novo Nordisk for obesity and type 2 diabetes
Cagrisema is an investigational combination therapy of cagrilintide (a long-acting amylin analogue) and semaglutide (a GLP-1 receptor agonist) being developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. By simultaneously targeting amylin and GLP-1 pathways, Cagrisema aims to deliver greater weight loss than either component alone. Phase 2 data and the ongoing Phase 3 REDEFINE programme have generated significant research interest, with reported weight loss exceeding that of semaglutide monotherapy.
The UK Peptide Starter Guide.
A plain-English introduction to research peptides written specifically for UK readers. Covers what they are, how they're classified, the legitimate vendors, the regulatory landscape — and the questions to ask before doing anything.
One welcome email, then the weekly briefing. Unsubscribe in one click. No vendor spam — ever.